Intradermal Rabies Booster for Previously Vaccinated Individuals
Yes, a rabies booster dose can be given intradermally to previously vaccinated individuals, but only with HDCV (human diploid cell vaccine) using the FDA-approved 0.1 mL intradermal formulation (Imovax Rabies I.D.), and only for preexposure booster situations—NOT for postexposure prophylaxis. 1
Critical Distinction: Preexposure vs. Postexposure Context
For Preexposure Booster Vaccination (Routine Boosters)
- One 0.1-mL intradermal dose of HDCV is approved and recommended for routine preexposure booster vaccination in previously vaccinated individuals 1
- The intradermal dose should be administered in the deltoid area (lateral aspect of upper arm) 1
- This applies to high-risk individuals requiring periodic boosters (laboratory workers, veterinarians, spelunkers) 1
- Both IM and ID routes are acceptable for preexposure boosters 1
For Postexposure Prophylaxis (After Rabies Exposure)
- Intradermal administration is NOT recommended for postexposure prophylaxis in previously vaccinated individuals 2
- The CDC explicitly recommends two 1.0-mL intramuscular doses (days 0 and 3) for postexposure treatment 1, 2
- This IM-only recommendation for postexposure treatment ensures rapid, reliable protection when mortality is at stake 2
Vaccine-Specific Restrictions
Only HDCV is approved for intradermal administration:
- HDCV (Imovax Rabies I.D.) has FDA approval for ID use since 1986 1
- RVA (rabies vaccine adsorbed) and PCEC (purified chick embryo cell vaccine) are NOT approved for intradermal use and should never be given ID 1
- The 1.0-mL vial of HDCV is not approved for multidose ID use 1
Important Contraindications for Intradermal Route
Antimalarial Drug Interactions
- HDCV should NOT be administered intradermally to persons taking chloroquine or structurally related antimalarials (e.g., mefloquine) 1
- These drugs decrease antibody response to concomitantly administered intradermal HDCV 1
- For travelers to malaria-endemic areas requiring both rabies prophylaxis and antimalarials:
Immunosuppressed Individuals
- Immunosuppressed persons should have antibody titers checked after vaccination regardless of route 1, 3
- Consider IM route for more reliable immune response in this population 1
Evidence Supporting Intradermal Boosters
Research demonstrates that intradermal boosters produce adequate immune responses:
- Cross-over studies show equivalent anamnestic responses whether switching from IM to ID or vice versa for booster doses 4
- Four-site intradermal booster regimens (using one-fifth diluent volume) produced significantly higher antibody titers than conventional IM boosters in some studies 5
- However, some data suggest lower early anamnestic responses with ID preexposure series, particularly in the first 5 days post-booster 6, 7
Practical Algorithm for Decision-Making
Use intradermal booster IF:
- Patient needs routine preexposure booster (not postexposure)
- HDCV (Imovax Rabies I.D.) is available
- Patient is NOT taking chloroquine or related antimalarials
- Patient is NOT immunosuppressed (or has documented adequate titers)
Use intramuscular booster IF:
- Postexposure prophylaxis is needed (always IM) 2
- Only RVA or PCEC vaccines are available 1
- Patient is taking antimalarial drugs 1
- Patient is immunosuppressed 1
- Intradermal formulation is unavailable
Common Pitfalls to Avoid
- Never use intradermal route for postexposure prophylaxis—this is the most critical error that could result in rabies death 2
- Do not attempt to divide the 1.0-mL vial for multiple ID doses—only the pre-packaged 0.1-mL formulation is approved 1
- Do not use RVA or PCEC intradermally under any circumstances 1
- Do not give ID boosters to patients on antimalarials without switching to IM route 1